Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022;12(3):261-290.
doi: 10.34172/bi.2022.23896. Epub 2022 Mar 26.

Recent advances in cancer immunotherapy: Modulation of tumor microenvironment by Toll-like receptor ligands

Leila Rostamizadeh  1 , Ommoleila Molavi  2   3 , Mohsen Rashid  1 , Fatemeh Ramazani  1 , Behzad Baradaran  4 , Afsaneh Lavasanaifar  5 , Raymond Lai  6
Affiliations
Review

Recent advances in cancer immunotherapy: Modulation of tumor microenvironment by Toll-like receptor ligands

Leila Rostamizadeh et al. Bioimpacts. 2022.

Abstract

Immunotherapy is considered a promising approach for cancer treatment. An important strategy for cancer immunotherapy is the use of cancer vaccines, which have been widely used for cancer treatment. Despite the great potential of cancer vaccines for cancer treatment, their therapeutic effects in clinical settings have been limited. The main reason behind the lack of significant therapeutic outcomes for cancer vaccines is believed to be the immunosuppressive tumor microenvironment (TME). The TME counteracts the therapeutic effects of immunotherapy and provides a favorable environment for tumor growth and progression. Therefore, overcoming the immunosuppressive TME can potentially augment the therapeutic effects of cancer immunotherapy in general and therapeutic cancer vaccines in particular. Among the strategies developed for overcoming immunosuppression in TME, the use of toll-like receptor (TLR) agonists has been suggested as a promising approach to reverse immunosuppression. In this paper, we will review the application of the four most widely studied TLR agonists including agonists of TLR3, 4, 7, and 9 in cancer immunotherapy.

Keywords: Agonist; Cancer; Immunotherapy; Microenvironment; TLRs; Vaccine.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Fig. 2
Fig. 2
Fig. 3
Fig. 3
See this image and copyright information in PMC

References

    1. Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24:541–50. doi: 10.1038/s41591-018-0014-x. - DOI - PMC - PubMed
    1. Damo M, Wilson DS, Simeoni E, Hubbell JAJSr. TLR-3 stimulation improves anti-tumor immunity elicited by dendritic cell exosome-based vaccines in a murine model of melanoma. Sci Rep. 2015;5:1–15. doi: 10.1038/srep17622. - DOI - PMC - PubMed
    1. Kobold S, Wiedemann G, Rothenfußer S, Endres S. Modes of action of TLR7 agonists in cancer therapy. Immunotherapy. 2014;6:1085–95. doi: 10.2217/imt.14.75. - DOI - PubMed
    1. Thompson JA, Kuzel T, Drucker BJ, Urba WJ, Bukowski RM. Safety and efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: an open-label, multicenter phase I/II study. Clin Genitourin Cancer. 2009;7:E58–65. doi: 10.3816/CGC.2009.n.025. - DOI - PubMed
    1. Why Cancer Immunotherapy? https://www.cancerresearch.org/immunotherapy/why-immunotherapy.

LinkOut - more resources